Trial Site Detail

 

Drug:
CB-839
Trial:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Conditions: Solid Tumors
Trial Status:
Active, not recruiting

 

Moffitt Cancer Center-International Plaza

     
Tampa , FL 33607
USA

 

Principal Investigator:
 Andrew S. Brohl
Contact:
 800-679-0775 canceranswers@moffitt.org
Activation Status of this Site:
 Closed
Notes about this Site:
Moffitt Cancer Center-International Plaza Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.